AbAccel is a cutting-edge optimization platform that is broadly applicable for the optimization of antibody drug candidates, even if they were not sourced from one of the AbCheck antibody libraries.

AbCheck has repeatedly achieved a 100-fold affinity improvement with its AbAccel platform. The AbAccel platform enables multi-factor antibody optimization in a single process, in order to increase the affinity while simultaneously addressing stability, species cross-reactivity, specificity and humanness to generate highly developable antibodies. Importantly, the platform can be used for both human and non-human lead antibodies.
AbAccel Optimizes Affinity While Preserving Other Drug-Relevant Properties
  Imprint Disclaimer